Graham Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Graham Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$537K	Buy	+861	New	+$586K	0.01%	691
2025 Q4	–	Sell	-712	Closed	-$400K	–	1541
2025 Q3	$400K	Buy	+712	New	+$403K	0.01%	706
2025 Q1	–	Sell	-1,506	Closed	-$1.07M	–	1479
2024 Q4	$1.07M	Buy	+1,506	New	+$1.26M	0.02%	478
2024 Q3	–	Sell	-389	Closed	-$409K	–	1300
2024 Q2	$409K	Sell	389 -1,149	-75%	-$1.11M	0.01%	645
2024 Q1	$1.48M	Sell	1,538 -402	-21%	-$382K	0.03%	311
2023 Q4	$1.7M	Buy	+1,940	New	+$1.6M	0.04%	245
2023 Q3	–	Sell	-864	Closed	-$621K	–	1245
2023 Q2	$621K	Buy	+864	New	+$666K	0.02%	497
2022 Q3	–	Sell	-3,128	Closed	-$1.85M	–	1275
2022 Q2	$1.85M	Buy	+3,128	New	+$2.03M	0.07%	228

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Graham Capital Management's REGN Position: Q2 2026 in Review

Graham Capital Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 861 shares worth $537K. The stake represents 0.01% of the portfolio and ranks #691 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in REGN as recently as Q3 2025.

Graham Capital Management first reported a position in REGN in Q2 2022 and has held it in 8 quarters since. The position peaked at $1.85M in Q2 2022. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Graham Capital Management held 861 shares of Regeneron Pharmaceuticals worth $537K as of Q2 2026.
Regeneron Pharmaceuticals was a new Graham Capital Management position in Q2 2026.
Regeneron Pharmaceuticals made up 0.01% of Graham Capital Management's portfolio in Q2 2026, its #691 holding.
Graham Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2022 and has held it in 8 quarters since.
Graham Capital Management's Regeneron Pharmaceuticals position peaked at $1.85M in Q2 2022.
1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.